AVI BioPharma and Lorus antisense deal

AVII and Lorus (TSE:LOR; LORFF) will evaluate and co-develop antisense compounds to treat cancer and infectious diseases. AVII brings its Neugene antisense backbone technology to the deal, while LOR b...